Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: How early is early in PsA?
Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment.
https://t.co/9d6WONarwL https://t.co/lNNKzblkEP
Dr. John Cush RheumNow
2 years 10 months ago
Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.
https://t.co/eSwcybRmX5 https://t.co/xEzMwIvAsK
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!
https://t.co/dXp0bDlnMW https://t.co/k0Jl7EX6zt
Dr. John Cush RheumNow
2 years 10 months ago
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/30S4si0Luy https://t.co/xlEVEJMoSp
Dr. John Cush RheumNow
2 years 10 months ago
Cardiac Troponin T and MACE Events in RA
Dr. Arthur Kavanaugh discusses abstract 0387 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/6ZcIQzsv4n https://t.co/34fFk3HTWy
Dr. John Cush RheumNow
2 years 10 months ago
According to AAMC, clinical neurophysiology has lowest (0.8) number of MDs/100K, while pediatrics has the highest (59.5). In a list of 52, Rheumatology is #17 at mean of 2 Rheums per 100,000 population https://t.co/BrrfSIeHb9 https://t.co/69kRSlk9Dq
For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.
Abstract #0494 provides context to our continual search for better understanding of inflammatory bowel disease in patients with AS, nr-AxSpA, and PsA.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Be sure to catch the early registration break for 2024 RheumNow Live.
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis
The window of opportunity concept in RA then shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes.
https://t.co/NTjYbMJJb6 https://t.co/TYuY1Q11xZ
Dr. John Cush RheumNow
2 years 10 months ago
Venous Thromboembolic Risk with Joint Replacement Save
A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding.
https://t.co/FKOsNkWMqz https://t.co/XH4SiQ735g
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease
AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis .
https://t.co/ZU0XFecPyP https://t.co/GLPsf73Hj0
Dr. John Cush RheumNow
2 years 10 months ago
Kuwait #RA registry study - shows in RA, the Uric acid level is inversely proportional to RA disease activity. 1054 RA pts, 15% had high UA level; lower DAS28 score associated w/ higher UA (p=0.032) OR 1.39; but higher HAQ assoc w/ higher UA https://t.co/muN0BFDs2Z https://t.co/VMdCgGPwPB
